For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Applied Molecular Transport Inc.

USPTO Granted Patents = 18

EPO Patents = 4

Forward Citations = 122

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Randall J Mrsny (18 out of 28 patents)

Tahir Mahmood (17 out of 20 patents)

Weijun Feng (8 out of 8 patents)

4. Sally Rhiannon Postlethwaite (7 out of 14 patents)

5. Charles Olson (5 out of 5 patents)

6. Thomas Carl Hunter (3 out of 3 patents)

7. Marvin R Garovoy (2 out of 14 patents)

8. Amir Porat (2 out of 2 patents)

9. Khushdeep Mangat (2 out of 2 patents)

10. Kevin Yin (2 out of 2 patents)

11. Bittoo Kanwar (2 out of 2 patents)

12. Hyojin Kim (2 out of 2 patents)

13. Rajendra Tandale (2 out of 2 patents)

14. Derek Maclean (2 out of 19 patents)

15. Sean Dalziel (2 out of 30 patents)

18 patents: Sort by Forward Citations

1. 11504433 - Cholix-derived carriers for oral delivery of heterologous payload (2022-11-22),

2. 11479593 - Compositions, formulations and interleukin production and purification (2022-10-25),

3. 11466067 - Compositions, formulations and interleukin production and purification (2022-10-11),

4. 11426466 - Toxin-derived delivery constructs for pulmonary delivery (2022-08-30),

5. 11324833 - Cholix-derived carriers for oral delivery of heterologous payload (2022-05-10),

6. 11246915 - Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo (2022-02-15),

7. 11214606 - Compositions, formulations and interleukin production and purification (2022-01-04),

8. 11160869 - Compositions, formulations and interleukin production and purification (2021-11-02),

9. 11027020 - Delivery constructs for transcytosis and related methods (2021-06-08),

10. 10799565 - Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo (2020-10-13),

11. 10786556 - Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo (2020-09-29),

12. 10786555 - Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo (2020-09-29),

13. 10624956 - Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo (2020-04-21),

14. 10624955 - Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo (2020-04-21),

15. 10617767 - Compositions and methods for oral delivery of therapeutic cargo (2020-04-14),

Company Overview

Applied Molecular Transport Inc. is a biotechnology company based in South San Francisco, California, focused on developing innovative therapeutics that leverage its proprietary transport technology. The company specializes in creating novel drug delivery systems aimed at enhancing the efficacy and safety of biologics and small molecules. By utilizing its advanced molecular transport platform, Applied Molecular Transport seeks to address significant unmet medical needs across various therapeutic areas, including immunology and oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

18 Patents

#74 in South San Francisco, CA

#4,288 in California

#17,963 in US

#34,217 in the World

South San Francisco, CA, United States of America

Applied Molecular Transport Inc.

Forward Citations = 122

18 inventors:

Randall J Mrsny (18 out of 28 patents)

Tahir Mahmood (17 out of 20 patents)

Weijun Feng (8 out of 8 patents)

4. Sally Rhiannon Postlethwaite (7 out of 14 patents)

5. Charles Olson (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Applied Molecular Transport Inc.. Retrieved from https://idiyas.com/company/applied-molecular-transport

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…